NewBiologix
Switzerland-based technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies
NewBiologix has raised €46M across 1 funding round from 3 investors, most recently a Series A round in May 2023. Based in Lausanne, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Lausanne, Switzerlandwww.newbiologix.com ↗
Total raised
€46M
€45,745,654
Funding rounds
1
Investors
3
distinct backers
Active since
2023-05
latest 2023-05
Funding by year
EUR raised per yearNewBiologix — funding by year — interactive chart.
Data table
| NewBiologix — funding by year | |
|---|---|
| 2023 | €46M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2023-05-11 | Series A | €46M | Igor Fish,Nicolas Mermod,Recipharm | View deal → |
Investors
3Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData